Ceta and pharmaceuticals
Impact of the trade agreement between Europe and Canada on the costs of prescription drugs
Bibliographic Data
| ID | 19533778 |
|---|---|
| Authors | Joel Lexchin (0000-0001-5120-8029, York University, corresponding author), Marc-André Gagnon (0000-0001-6113-4772, Carleton University) |
| Year | 2014 |
| Volume | 10 |
| Issue | 1 |
| Pages | 30 |
| Publication date | 2014-01-01 |
| Peer Reviewed | Yes |
| Open Access | Yes |
| Type | ARTICLE |
| Venue | Globalization and Health (JOURNAL) |
| Journal identifiers | ISSN: 1744-8603 • E-ISSN: 1744-8603 |
| Publisher | Springer Science and Business Media LLC (PUBLISHER) |
| DOI | 10.1186/1744-8603-10-30 |
| PMID | 24885309 |
| PMCID | PMC4108121 |
| OpenAlex | W2149452892 |
| Language | EN |
| Citations received | 11 |
| References cited | 4 |
On a per capita basis, Canadian drug costs are already the second highest in the world after the United States and are among the fastest rising in the Organization for Economic Co-Operation and Development. The Comprehensive Economic and Trade Agreement (CETA) between the European Union (EU) and Canada will further exacerbate the rise in costs by: Committing Canada to creating a new system of patent term restoration thereby delaying entry of generic medicines by up to two years; Locking in Canada's current term of data protection, and creating barriers for future governments wanting to reverse it; Implementing a new right of appeal under the patent linkage system that will create further delays for the entry of generics.CETA will only affect intellectual property rights in Canada-not the EU. This analysis estimates that CETA's provisions will increase Canadian drug costs by between 6.2% and 12.9% starting in 2023. The Canadian government committed to compensating provinces for the rise in costs for their public drug plans. Importantly, this means that people paying out-of-pocket for their drugs or receiving them through private insurance, will be charged twice: once through higher drug costs and once more through their federal taxes.As drug costs continue to grow, there are limited options available for provincial/territorial governments: restrict the choice of medicines in public drug plans; transfer costs to patients who typically are either elderly or sick; or take money from other places in the health system, and threaten the viability of Canada's single payer system. CETA will therefore negatively impact the ability of Canada to offer quality health care
Appeal · Business · Economic growth · Economic policy · Economics · Environmental health · European union · International trade · Medical prescription · Per capita · Political science · Population · Public economics · Public health · Health Systems, Economic Evaluations, Quality of Life · Healthcare Policy and Management · Law · Medicine · Pharmaceutical Economics and Policy
The Trans Pacific Partnership Agreement, intellectual property and medicines
A conceptual framework for investigating the impacts of international trade and investment agreements on noncommunicable disease risk factors
A stakeholder-based view of the evolution of intellectual property institutions
Trade, investment and the global economy
Media and neoliberal hegemony
The Trans Pacific Partnership Agreement and access to HIV treatment in Vietnam
Intellectual property and access to medicines
Defending access to medicines in regional trade agreements
What is the impact of intellectual property rules on access to medicines? A systematic review
Analyzing the impact of trade and investment agreements on pharmaceutical policy
Glossary on free trade agreements and health part 2
| Unique citing works | 11 |
|---|---|
| Citations per year | 1.1 |
| Citation span | 2016 - 2022 (7) |
| Citation velocity | historical |
| Highly cited | No |
| Citation types | Neutral: 10 |